PTK 2015 Banner 
2015 Peptalk M Banner 

Pipeline Two Icon Pipeline Two Header 

Cambridge Healthtech Institute’s 4th Annual
Bispecific Antibody Therapeutics
Engineering Multispecificity
January 22-23, 2015


Creating bioactive molecules that are multivalent and multifunctional offers the promise of more effective therapeutics. By binding to at least two molecular targets simultaneously, antibodies are empowered, thereby delivering a highly potent therapeutic, particularly for cancer immunotherapy. This Bispecific Antibody Therapeutics conference explores the challenges of engineering multispecificity to ensure stability and efficacy, and reviews the numerous forms of multispecific antibodies. The conference gives particular focus to safety issues, as well as PK and immunogenicity. Case studies highlight preclinical development as well as clinical data.

Preliminary Agenda 


BISPECIFICS FOR ONCOLOGY 


KEYNOTE PRESENTATION

Cancer Immunotherapy with Bispecific T Cell Engager (BiTE®) Antibodies

Dirk Nagorsen, M.D., Ph.D., Global Development Leader, Global Clinical Development, Amgen Research Munich GmbH


A Novel Fc-Containing Bispecific Format with Full-Length Antibody Properties: Applications in Oncology

David Szymkowski, Ph.D., Senior Director, Biotherapeutics, Xencor, Inc.


Enhanced Tumor Cell Killing via Selective Inhibition of CD47 with Bispecific Antibodies

Nicolas Fischer, Ph.D., Head, Research, Novimmune SA


A New Platform to Automate Bispecific Antibody Design and Assessment

Christopher Smith, Ph.D., Senior Scientific Consultant, Biologics, Genedata


BISPECIFIC BREAKTHROUGHS 

MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Adaptations in
Growth Factor Signaling Networks

Alexey A. Lugovskoy, Ph.D., Vice President, Therapeutics and MM-141 Project Leader, Merrimack Pharmaceuticals, Inc.


Therapeutic Fully Human Bispecific Antibodies with Two Binding Sites in Each Fv Region

Kristian Jensen, Ph.D., Vice President, Project Management, R&D, Dutalys GmbH


A Novel and Generic Approach for the Generation of Monovalent Bispecific IgG

Yariv Mazor, Ph.D., Scientist, Antibody Discovery and Protein Engineering, Medimmune


PROGRESSIVE ENGINEERING 

Nonclinical Development of Multi-Targeting Biotherapeutics: More Targets, More Complexity

Rodney Prell, Ph.D., Senior Scientist, Toxocology, Genentech, Inc.


Engineering Bispecific Antibody through Electrostatic Steering Mechanism:
Heavy Chain Heterodimerization and Light – Heavy Chain Pairing

Gunasekaran Kannan, Ph.D., Principal Scientist and Group Leader, Biologics Optimization, Amgen, Inc.


Computer-Based Design of Bispecific Antibodies

Brian Kuhlman, Ph.D., Professor, Biochemistry and Biophysics, University of North Carolina School of Medicine


NON-ONCOLOGY APPLICATIONS 

Novel Approach to Hemophilia A Treatment: ACE910, an Asymmmetric Bispecific IgG
to Coagulation Factors IXa and X

Yukiko Okuyama-Nishida, Ph.D., Sub Lifecycle Leader, Primary Lifecycle Management, Chugai Pharmaceutical Co., Ltd.


PLATFORM TECHNOLOGY 

DuoBody® Platform: A Versatile Platform for Lead Discovery in the Final Format

Aran F. Labrijn, Ph.D., Senior Scientist, Antibody Sciences, Genmab BV

Preclinical Development of a Fully Human Bispecific Antibody Platform

Eric Smith, Ph.D., Associate Director, Bispecifics, Regeneron Pharmaceuticals, Inc.